Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
CLN-619 will be the first MICA/B-targeted antibody to enter human clinical trialsCullinan will initiate a FIH trial in 3Q21, including...